CDA and Hyperbilirubinemia: However, Pellicer et al., (Caucasian population; Spain; n = 301) reported that patients with CRC carrying the CDA rs1048977-T allele (p = 0.044; OR = 8.62; 95% CI = 1.05–70.24; CC vs. T) presented a higher risk of capecitabine toxicity, particularly hyperbilirubinemia [24].